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ABSTRACT 
 
Transforming growth factor-β (TGF-β) is a key factor for understanding the pathogenesis of 
fibrotic disorders such as idiopathic pulmonary fibrosis (IPF). We have demonstrated that 
interleukin-10 (IL-10) suppresses TGF-β-induced expression of type I collagen (COL1) 
mRNA in a human lung fibroblast cell line (WI-38). However, the inhibitory mechanism has 
not yet been clearly elucidated. Thus, in the current study, we investigate the effects of IL-10 
blockade of TGF-β signaling which regulates COL1 mRNA expression. In WI-38 cells, IL-10 
inhibits TGF-β-mediated phosphorylation of both, c-Jun HN2-terminal kinase (JNK) and p38, 
but does not suppress TGF-β-mediated phosphorylation of Smad2 or affect 
TGF-β-upregulation of Smad7 mRNA expression. In addition, SP600125 and SB203580, 
specific inhibitors of JNK and p38, respectively, attenuate TGF-β-induced COL1 mRNA 
expression in WI-38 cells. These results suggest that IL-10 inhibits TGF-β-induced COL1 
mRNA expression via both JNK and p38 pathways but not Smad pathways in WI-38 cells. 
This inhibitory mechanism may provide a novel insight into therapeutic strategies for fibrotic 
disorders such as IPF. 
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INTRODUTION 
 
Idiopathic pulmonary fibrosis (IPF) is a 
devastating disease characterized by poor 
prognosis with a median survival of only two 
to three years (Bjoraker et al., 1998; Douglas 
et al., 2000; Schwartz et al., 1994) and by an 
unknown etiology. Transforming growth 
factor-β (TGF-β) is a key factor for 
understanding the pathogenesis of IPF. 
Immunohistochemical staining of TGF-β in 
lung sections of patients with IPF 
demonstrates a marked and consistent 
increase in TGF-β production in epithelial 
cells and macrophages compared to patients 
with nonspecific inflammation and to those 
with no inflammation or fibrosis (Khalil et al., 
1991). In addition, we (Yoshida et al., 1995) 
and others (Sime et al., 1997) have found that 
overexpression of TGF-β in rat lungs results 
 
 
 50
in pulmonary fibrosis characterized by 
excessive accumulation of extracellular 
matrix (ECM) and limited inflammation. 
Type I collagen (COL1) is a major structural 
component of ECM and is synthesized by 
various cells including fibroblasts. TGF-β 
regulates COL1 gene expression in 
fibroblasts (Ignotz et al., 1987). However, the 
role of TGF-β signaling in COL1 gene 
expression in fibroblasts is not clearly 
understood. 
 
TGF-β signaling is initiated following the 
binding of TGF-β to its membrane-bound 
receptors, which are classified as type I and 
type II receptors. TGF-β binding to the type 
II receptor recruits the type I receptor into a 
complex that results in phosphorylation of 
the transcription factors, Smad2 or Smad3. 
The phosphorylation of either Smad2 or 
Smad3 causes it to associate with Smad4. 
The complex translocates into the nucleus, 
where it regulates transcriptional responses 
together with additional DNA binding 
cofactors (Derynck et al., 1998). On the other 
hand, Smad7 is an intracellular antagonist for 
TGF-β signaling. Smad7 interferes directly 
with TGF-β-mediated activation of Smad2 
by preventing its phosphorylation, 
association with Smad4, and nuclear 
accumulation (Hayashi et al., 1997; Nakao et 
al., 1997). 
 
In addition to classical Smad pathways, 
mitogen-activated protein kinase (MAPK) 
pathways function downstream of TGF-β 
signaling (Engel et al., 1999; Hanafusa et al., 
1999; Hu et al., 1999). The three major 
MAPK pathways have been characterized: 
extracellular signal-regulated kinase (ERK), 
c-Jun HN2-terminal kinase (JNK) and p38.  
ERK plays a major role in cell proliferation 
(Portnoy et al., 2004) and differentiation 
(Kim et al., 1997) as well as in survival 
(Ahmad et al., 2004) mediated by various 
growth factors. On the other hand, JNK and 
p38 are activated by environmental stressors 
such as osmotic shock (Kultz et al., 1997), 
ultraviolet (UV) irradiation (Seo et al., 2002) 
and by pro-inflammatory cytokines including 
tumor necrosis factor-α (TNF-α) 
(Goukassian et al., 2003) and interleukin-1 
(IL-1) (Li et al., 2003), and play a critical 
role in apoptosis (Ichijo et al., 1997) and 
cytokine induction (Masuda et al., 2002). 
 
Interleukin-10 (IL-10), first recognized for its 
ability to inhibit the activation and effector 
function of T cells, monocytes, and 
macrophages, is a multifunctional cytokine 
with diverse effects on most hematopoietic 
cell types. The principal function of IL-10 is 
to limit and ultimately terminate 
inflammatory responses (Moore et al., 2001). 
In addition to these activities, IL-10 
modulates COL1 gene expression in skin 
fibroblasts (Reitamo et al., 1994; Wangoo et 
al., 1997). We have focused our attention on 
this effect of IL-10 and demonstrated that 
IL-10 suppresses TGF-β-induced COL1 
mRNA expression in a human lung fibroblast 
cell line (WI-38) (Arai et al., 2000). However, 
the inhibitory mechanism of IL-10 on 
TGF-β-induced COL1 mRNA expression has 
not yet been clearly elucidated. This 
inhibitory mechanism may provide a novel 
insight into therapeutic strategies for fibrotic 
disorders such as IPF. Thus, in the current 
study, we investigate IL-10 blockade of 
TGF-β signaling which regulates COL1 
mRNA expression in WI-38 cells. 
 
MATERIALS AND METHODS 
 
Cell culture 
WI-38, a human lung fibroblast cell line, 
purchased from Health Science Research 
Resources Bank (Osaka, Japan) was cultured 
in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 U/ml penicillin and 
10 µg/ml streptomycin at 37°C in a 
humidified atmosphere of 95% air and 5% 
CO2. 
 
RNA preparation and Reverse transcription 
(RT) 
WI-38 cells were seeded in DMEM 
containing 10% FBS at a density of 4×105 
cells on a 60 mm-dish. Before confluence 
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was reached, the cells were starved for 24 h, 
and then treated with 10 ng/ml human 
TGF-β1 (Sigma, St. Louis, Mo). In some 
experiments, the cells were preincubated 
with recombinant human IL-10 (Wako, 
Osaka, Japan), 10 µM SB203580 or 10 µM 
SP600125 (Calbiochem, San Diego, CA) for 
one hour before the administration of TGF-β1. 
Total RNA from the cells was isolated with 
Isogen® (Nipponegene, Tokyo, Japan) 
according to the manufacturer’s protocol. 
Total RNA (1 µg) was reverse-transcribed 
with 25 µg/ml Oligo(dT)12-18 (Invitrogen, 
Carlsbad, CA), 1× First strand Buffer 
(Invitrogen), 10 mM dithiothreitol, 0.5 mM 
deoxynucleotide triphosphates (dNTPs) and 
5 U/ml SuperScript™ III (Invitrogen). 
 
Polymerase chain reaction (PCR) 
The cDNA mixture was subject to PCR 
amplification with following specific 
primers: sense 
5'-CTGGTCCCAAGGGTAACAG-3' and 
antisense 
5'-GCCAGGAGAACCACGTTC-3' for 
human COL1, sense 
5'-TGCCTCCTGCACCACCAACTGC-3' 
and antisense 
5'-AATGCCAGCCCCAGCGTCAAAG-3' 
for human glyceraldehyde-3-phospate 
dehydrogenase (GAPDH), and sense 
5'-AAAGTGTTCCCTGGTTTCTCCATCAA
GGC-3' and antisense 
5'-CTACCGGCTGTTGAAGATGACCTCC
AGCCAGCAC for human Smad7.  The 
PCR cycles and the annealing temperature 
for each primer were as follows: 32 cycles at 
58°C for COL1, 30 cycles at 65°C for Smad7, 
and 25 cycles at 60°C for GAPDH. After 
amplification, the PCR products were 
separated by electrophoresis on 2% agarose 
gels containing ethidium bromide. The 
density of the bands was quantified with 
FLUOR CHEM™ (Alpha Innotech, San 
Leandro, CA). The relative expression of 
COL1 and Smad7 mRNAs was quantified by 
assessing the ratio of the density of the COL1 
and Smad7 bands, respectively, to GAPDH 
bands. 
 
Protein extraction and Western blot analysis 
WI-38 cells were seeded in DMEM 
containing 10% FBS at a density of 4×105 
cells on a 60 mm-dish. Before confluence 
was reached, the cells were starved for 24 h, 
then treated with 10 ng/ml TGF-β1 at various 
times in the presence or absence of 20 ng/ml 
IL-10. The cells were lysed with 100 µl RIPA 
buffer containing 20 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 2 mM EDTA, 1% Nonident 
P-40, 1% sodium deoxycholate, 0.1% sodium 
dodecylsulfate (SDS), 1 mM 
phenylmethylsulfonylfluoride, 0.04 TIU/µl 
aprotinin, 1 mM sodium orthovanadate and 
50 mM sodium fluoride. Protein 
concentrations were measured with the 
Detergent-Compatible (DC) protein assay 
(Bio-Rad, Hercules, CA).  Samples were 
separated on 10% SDS-polyacrylamide gels 
and transferred to polyvinylidene difluoride 
membranes (Millipore, Bedford, MA). The 
membranes were incubated with rabbit 
primary antibodies against phospho-JNK, 
phospho-p38, phospho-ERK and 
phospho-Smad2 (all from Cell Signaling, 
Beverly, MA) at a 1:200 dilution for 1 h at 
room temperature, followed by incubation 
for another 1 h at room temperature with 
donkey anti-rabbit horseradish 
peroxidase-conjugated secondary antibodies 
(Amersham, Piscataway, NJ) at a 1:2,000 
dilution. The proteins were visualized after 
incubation of the blots using an enhanced 
chemiluminescence (ECL) system 
(Amersham). To determine the total amounts 
of JNK, p38, ERK, and Smad2, the blots 
were stripped and reprobed using antibodies 
against JNK, p38, ERK (Santa Cruz, Santa 
Cruz, CA), and Smad2 (Zymed, South San 
Francisco, CA) at a 1:1,000 dilution. 
 
Statistical analysis 
Data were expressed as means ± SD. 
Comparisons among groups were by ANOVA 
with Bonferroni/Dunn’s tests used for post 
hoc analyses. Significance was accepted p 
<0.01. 
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RESULTS 
 
IL-10 inhibits TGF-β-induced COL1 mRNA 
expression in WI-38 cells. 
We previously reported that TGF-β enhanced 
COL1 mRNA expression, and that IL-10 
suppressed TGF-β-induced COL1 mRNA 
expression in a dose-dependent manner (Arai 
et al., 2000). To confirm that IL-10 inhibits 
TGF-β-induced COL1 mRNA expression, 
WI-38 cells were treated with TGF-β in the 
presence or absence of IL-10 for 24 h. The 
amounts of COL1 mRNA were determined 
by RT-PCR. As expected, TGF-β treatment 
increased expression of COL1 mRNA (Fig. 
1). IL-10 decreased TGF-β-induced COL1 
mRNA expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effects of IL-10 on 
TGF-β-induced COL1 mRNA expression. 
WI-38 cells were treated with 10 ng/ml 
TGF-β in the presence or absence of 20 
ng/ml IL-10 for 24 h. The amounts of 
COL1 mRNA were evaluated by RT-PCR, 
and expression was quantified by 
assessing the ratio of the density of 
COL1 bands to GAPDH bands. (A) 
Representative COL1 and GAPDH bands 
treated with TGF-β in the presence or 
absence of IL-10. (B) Ratio of the density 
of COL1 bands to GAPDH bands. Values 
represent means ± SD of 3 independent 
experiments. ** p <0.001 control vehicle 
vs. TGF-β. 
 
IL-10 does not inhibit TGF-β-mediated 
phosphorylation of Smad2 in WI-38 cells 
TGF-β signaling through Smad2 is initiated 
when the type I receptor kinase, activated by 
receptor II-mediated transphosphorylation, 
directly phosphorylates Smad2 at Ser465/467 
(Macias-Silva et al., 1996). Many of the 
effects of TGF-β are mediated through Smad 
pathways. To determine Smad2 
phosphorylation by TGF-β, WI-38 cells were 
treated with TGF-β at various times, and 
Western blot analysis was carried out using 
anti-phospho-Smad2 antibodies. As shown in 
Fig. 2A, Smad2 phosphorylation was 
increased at 15 min, reached a maximum at 
30 min and remained elevated for up to 120 
min after TGF-β treatment. 
 
To determine whether IL-10 could block 
TGF-β-mediated Smad2 phosphorylation, 
WI-38 cells were preincubated with IL-10 
before TGF-β treatment As shown in Fig. 2B, 
IL-10 did not decrease the amounts of 
TGF-β-mediated Smad2 serine 
phosphorylation. 
 
IL-10 does not affect TGF-β-upregulation of 
Smad7 mRNA expression in WI-38 cells 
Smad7 is an intracellular antagonist for 
TGF-β signaling. Smad7 functions by 
associating with the activated TGF-β type I 
receptor to block access to and 
phosphorylation of Smad2 (Hayashi et al., 
1997; Nakao et al., 1997). To investigate 
whether IL-10 could affect the 
TGF-β-mediated Smad7 pathway, WI-38 
cells were treated with TGF-β in the presence 
or absence of IL-10 for 24 h. The amounts of 
Smad7 mRNA were determined by RT-PCR. 
As shown in Fig. 3, TGF-β increased 
expression of Smad7 mRNA. However, 
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IL-10 did not affect TGF-β-upregulation of 
Smad7 mRNA expression. This result 
together with the result of Fig. 2 indicates 
that IL-10 does not affect TGF-β-mediated 
Smad pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effects of IL-10 on TGF-β-mediated phosphorylation of Smad2. WI-38 cells 
were treated with 10 ng/ml TGF-β at various times in the presence or absence of 20 
ng/ml IL-10. The amounts of phospho-Smad2 were evaluated by Western blotting. (A) 
Time course of phosphorylated Smad2 induced by TGF-β. (B) Effects of IL-10 on 
TGF-β-induced phosphorylation of Smad2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Effects of IL-10 on TGF-β-mediated mRNA expression of Smad7. WI-38 
cells were treated with 10 ng/ml TGF-β in the presence or absence of 20 ng/ml IL-10 
for 24 h. Smad7 mRNA was evaluated by RT-PCR, and expression was quantified by 
assessing the ratio of the density of Smad7 bands to GAPDH bands. (A) 
Representative Smad7 and GAPDH mRNA expression. (B) Densitometric analysis of 
Smad7 mRNA expression. Values represent means ± SD of 3 independent 
experiments. ** p <0.001 control vehicle vs. TGF-β. N.S. TGF-β vs. TGF-β plus IL-10. 
N.S. stands for Not Significant. 
 
TGF-β results in phosphorylation of JNK and 
p38, but not ERK in WI-38 cells.  
In addition to classical Smad pathways, it has 
been demonstrated in various cell types that 
TGF-β is capable of activating each of the 
MAPK pathways (Engel et al., 1999; 
Hanafusa et al., 1999; Hu et al., 1999). To 
determine whether TGF-β could activate 
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JNK, p38 and ERK, WI-38 cells were treated 
with TGF-β at various times, and Western 
blot analysis was carried out using 
anti-phospho-JNK, anti-phospho-p38, and 
anti-phospho-ERK antibodies, respectively. 
As shown in Fig. 4A, the amounts of 
phosphorylated JNK increased at 5 min, 
reached a maximum at 15 min and remained 
elevated for up to 120 min after TGF-β 
treatment. As shown in Fig. 4B, the amounts 
of phosphorylated p38 increased at 30 min, 
reached a maximum at 60 min and remained 
elevated for up to 120 min after TGF-β 
treatment. However, TGF-β did not 
phosphorylate ERK threonine/tyrosine 
residues (Fig. 4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effects of TGF-β on JNK, p38 and ERK. WI-38 cells were treated with 10 
ng/ml TGF-β at various times. Phosphorylation of JNK, p38, and ERK was assessed 
by Western blotting using specific antibodies against phospho-JNK, phospho-p38 and 
phospho-ERK. (A) Amounts of phosphorylated JNK (46 kDa) (B) Amounts of 
phosphorylated p38 (C) Amounts of phosphorylated ERK1 (upper band, 44 kDa) and 
ERK2 (lower band, 42 kDa). 
 
IL-10 inhibits TGF-β-mediated 
phosphorylation of both JNK and p38 in 
WI-38 cells 
To determine whether IL-10 could block the 
TGF-β-mediated the JNK pathway or/and the 
p38 pathway, WI-38 cells were treated with 
TGF-β after a 60 min pre-incubation with 
IL-10. Western blot analysis was carried out 
using anti-phospho-JNK and anti-JNK 
antibodies as well as anti-phospho-p38 and 
anti-p38 antibodies. As shown in Fig. 5A, 
IL-10 decreased the amounts of 
TGF-β-induced phosphorylation of JNK. In 
addition IL-10 also reduced the amounts of 
TGF-β-mediated phosphorylation of p38 (Fig. 
5B). 
 
 
Specific inhibitors of JNK and p38, 
SP600125 and SB203580, respectively, 
attenuate TGF-β-induced COL1 mRNA 
expression in WI-38 cells 
Finally, to determine whether the JNK 
pathway and/or the p38 pathway could 
regulate TGF-β-induced COL1 mRNA 
expression, WI-38 cells were treated with 
TGF-β in the presence or absence of 10 µM 
SP600125, a specific inhibitor of JNK (Han 
et al., 2001) or 10 µM SB203580, a specific 
inhibitor of p38 (Lee et al., 1994) for 24 h. 
The amounts of COL1 mRNA were 
determined by RT-PCR. As shown in Fig. 6A 
and B, SP600125 inhibited TGF-β-induced 
COL1 mRNA expression. In addition, 
SB203580 also suppressed TGF-β-induced 
COL1 mRNA expression (Fig. 6C and D). 
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These results indicate that both JNK and p38 
pathways are involved in TGF-β-induced 
COL1 mRNA expression, suggesting that 
IL-10 inhibits TGF-β-induced COL1 mRNA 
expression via both JNK and p38 pathways.
 
 
 
 
 
 
 
 
 
 
Figure 5: Effects of IL-10 on TGF-β-mediated phosphorylation of JNK and p38. WI-38 
cells were treated with 10 ng/ml TGF-β following a 60 min pre-incubation of 20 ng/ml 
IL-10. Western blots were performed using phospho-JNK and JNK antibodies as well 
as phospho-p38 and p38 antibodies. (A) Effect of IL-10 on TGF-β-mediated 
phosphorylation of JNK (46 kDa). (B) Effect of IL-10 on TGF-β-mediated 
phosphorylation of p38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Effects of JNK and p38 inhibitors on TGF-β-induced COL1 mRNA 
expression. WI-38 cells were treated with 10 ng/ml TGF-β in the presence or absence 
of 10 µM SP600125 as a JNK inhibitor or 10 µM SB203580 as a p38 inhibitor for 24 h. 
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The amounts of COL1 mRNA were evaluated by RT-PCR and expression was 
quantified by assessing the ratio of the density of COL1 bands to GAPDH bands. 
Values represent means ± SD of 3 independent experiments. (A) Representative 
COL1 and GAPDH bands treated with control vehicle, TGF-β or TGF-β plus 
SP600125. (B) Ratio of density of COL1 bands to that of GAPDH bands. * p <0.01 
control vehicle vs. TGF-β, TGF-β vs. TGF-β plus SP600125. (C) Representative 
COL1 and GAPDH bands treated with control vehicle, TGF-β or TGF-β plus 
SB203580. (D) Ratio of density of COL1 bands to that of GAPDH bands. * p <0.01 
control vehicle vs. TGF-β, TGF-β vs. TGF-β plus SB203580. 
 
DISCUSSION 
 
There is accumulating evidence that IL-10 
reduces TGF-β-induced COL1 gene 
expression in fibroblasts (Arai et al., 2000; 
Yamamoto et al., 2001). However, the IL-10 
inhibitory mechanism of TGF-β-induced 
COL1 gene expression in fibroblasts has not 
yet been clearly established. Elucidation of 
this inhibitory mechanism may provide novel 
insight into therapeutic strategies for fibrotic 
disorders such as IPF. Thus, in the current 
study we investigate IL-10 blockade of 
TGF-β signaling which regulates COL1 
mRNA expression. In WI-38 cells, IL-10 
inhibits TGF-β-mediated phosphorylation of 
both JNK and p38, but does not suppress 
TGF-β-mediated phosphorylation of Smad2 
or affect TGF-β-upregulation of Smad7 
mRNA expression. In addition, specific 
inhibitors of JNK and p38 decrease 
TGF-β-induced COL1 mRNA expression. 
These results indicate that IL-10 inhibits 
TGF-β-induced COL1 mRNA expression via 
both JNK and p38 pathways but not Smad 
pathways. 
 
Smad pathways have been reported to 
mediate TGF-β-induced COL1 gene 
expression, although the role of TGF-β 
signaling in COL1 gene expression is not 
clearly understood. Overexpression of Smad7 
in renal tubular epithelial cells reduces COL1 
mRNA expression with a marked inhibition 
of TGF-β-mediated Smad2 activation (Li et 
al., 2002). Gene transfer of Smad7 prevents 
bleomycin-induced lung fibrosis (Nakao et 
al., 1999), suggesting that Smad7 may have 
applicability in the treatment of pulmonary 
fibrosis. In WI-38 cells, IL-10 does not 
suppress TGF-β-induced phosphorylation of 
Smad2 or affect TGF-β upregulation of 
Smad7 mRNA expression. In this study, we 
demonstrate that IL-10 does not affect 
TGF-β-Smad pathways, indicating that the 
other mechanisms are involved in the 
inhibitory effect of IL-10 on COL1 gene 
expression. 
 
In addition to classical Smad pathways, 
TGF-β is capable of activating each of the 
three MAPK pathways in various cell types 
including lung fibroblasts. TGF-β results in 
phosphorylation of JNK and p38, but not 
ERK in a human lung fibroblast cell line 
(HLF-1) (Utsugi et al., 2003) as well as in 
phosphorylation of JNK, p38 and ERK in 
another human lung fibroblast cell line 
(HLF) (Hashimoto et al., 2001). In WI-38 
cells, TGF-β activates JNK and p38, but not 
ERK. TGF-β-activated kinase 1 (TAK1) was 
first identified as one of the MAPK kinase 
kinase family (Yamaguchi et al., 1995) and 
appears preferably to be an upstream 
regulator of JNK (Wang et al., 1997) and p38 
(Hanafusa et al., 1999) pathways in TGF-β 
signaling.  In TGF-β-stimulated WI-38 cells, 
it is possible that TAK1 regulates JNK and 
p38 phosphorylation and activation. 
 
IL-10 has been found to inhibit MAPK 
pathways activated by several stimuli in 
different cell types. IL-10 suppresses 
LPS-induced p38 phosphorylation in 
macrophages (Kontoyiannis et al., 2001) and 
IL-1β-stimulated JNK activation in brain 
tissue (Kelly et al., 2001). In TGF-β-treated 
WI-38 cells, IL-10 inhibits both JNK and p38 
phosphorylation. The effects of IL-10 are 
mediated by the IL-10 receptor on the target 
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cells including human fibroblasts (Wang et 
al., 1999). Activation of the IL-10 receptor 
has been found to activate the JAK-STAT 
pathway (Finbloom et al., 1995). The 
detailed mechanism by which IL-10 targets 
TGF-β-mediated both the JNK and p38 
pathways has not been investigated in the 
current study. IL-10 signaling could directly 
interfere with TGF-β-mediated JNK and p38 
pathways. However, further studies are 
needed to clarify how IL-10 interferes with 
TGF-β-mediated JNK and p38 pathways. 
 
MAPK has been also demonstrated to 
modulate COL1 gene expression by several 
stimuli in mammalian cells, although the role 
of TGF-β signaling in COL1 gene expression 
is not clearly understood. JNK modulates 
UV-induced gene expression of COL1 in rat 
hepatic stellate cells (Chen et al., 1999). 
Moreover, p38 regulates both TNFα-induced 
and TGF-β-induced COL1 gene expression 
in the same cell line (Varela-Rey et al., 2002). 
In our study, inhibition of either JNK or p38 
reduces TGF-β-induced COL1 mRNA 
expression. Our findings indicate that both 
JNK and p38 are important for modulating 
TGF-β-induced COL1 mRNA expression. 
This concept is supported by recent evidence 
that a dominant negative TAK1, which 
appears to be an upstream regulator of JNK 
(Wang et al., 1997) and p38 (Hanafusa et al., 
1999) pathways in TGF-β signaling, inhibits 
cellular fibrotic responses induced by TGF-β 
(Ono et al., 2003). Given that no exogenous 
Smad inhibitor exists to date, one of the new 
insights that our study has provided is the 
clarification of the inhibitory mechanism of 
IL-10. JNK and p38 inhibitors, which already 
do exist, may represent a more feasible 
therapeutic strategy for fibrotic disorders 
such as IPF. 
 
FR167653 was first discovered as a cytokine 
suppressive agent in vivo (Yamamoto et al., 
1996), which was later found to resemble the 
chemical structure of SB203580 to belong to 
one of p38 inhibitors (Takahashi et al., 2001). 
Our previous investigations demonstrated 
that both IL-10 (Arai et al., 2000) and 
FR167653 (Matsuoka et al., 2002) suppress 
bleomycin-induced pulmonary fibrosis in a 
murine model. These similar in vivo findings 
can be explained by our new in vitro 
evidence that both IL-10 and SB203580 
reduce TGF-β-induced COL1 mRNA 
expression, because in this model bleomycin 
has been demonstrated to induce a 
TGF-β-dependent induction of pulmonary 
fibrosis with increased collagen and 
hydroxyproline synthesis (Kolb et al., 2001). 
 
In conclusion, IL-10 suppresses 
TGF-β-induced COL1 mRNA expression via 
both JNK and p38 pathways but not Smad 
pathways in WI-38 cells. This inhibitory 
mechanism may provide a new insight into 
therapeutic strategies for fibrotic disorders 
such as IPF. 
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